摘要
目的:探讨柴胡疏肝散对肝纤维化作用及其机制。方法:60只大鼠随机分为6组:正常对照组、病理模型组、秋水仙碱组、柴胡疏肝散各治疗组(3.15、6.3、12.6 g/kg)。除正常对照组外,其余各组均采用猪血清腹腔注射诱发肝纤维化,0.5ml/只,2次/周,连续10周,5周后即可形成肝纤维化。各治疗组于造模第6周给药,持续至第10周。秋水仙碱治疗组剂量0.05 mg/kg,柴胡疏肝散各治疗组(3.15、6.3、12.6 g/kg)。采用酸性水解法检测肝组织羟脯氨酸(hydroxyproline,HYP)含量;放射免疫法(RIA)检测肝组织白介素-1(IL-1)和肿瘤坏死因子-α(TNF-α)含量;原位杂交、免疫组化法分别检测肝组织转化生长因子-β1(TGF-β1)和α-平滑肌肌动蛋白(α-SMA)mRNA与蛋白表达。结果:与模型组比较,柴胡疏肝散6.3 g/kg剂量组HYP(557.32±3.21 vs 376.32±3.32,P<0.01)、IL-1(0.98±0.51 vs 0.35±0.54,P<0.05)和TNF-α(5.31±0.52 vs 4.23±0.38,P<0.05)含量均显著降低,TGF-β1mRNA(10.51±1.79 vs 5.56±2.43,P<0.01)和α-SMA mRNA(14.31±2.31 vs 6.33±0.72,P<0.01)及其蛋白表达显著减弱。结论:柴胡疏肝散有明显的抗肝纤维化作用,其机制可能与抑制IL-1和TNF-α释放,阻遏TGF-β1和α-SMA基因表达有关。
Objective： To investigate the effects and mechanism of Chaihushugansan（ CHSGS） on hepatic fibrosis in rats. Method： The immunohepatic fibrosis model was induced by intraperitoneal injection of porcine serum. in to rats. 70 wister rats were divided into seven groups： normol control,model,CHSGS high-dose,mediate-dose and low-dose,prevention group,colchicin contrast group. Except the normol control groups,all the other groups were injected with pig’s serum without inactivation into abdominal cavity,twice per week and 0. 5ml each time,persisting for 10 weeks. The prevention groups were injected the stomach with the medicines（ CHSGS 6. 3 g / kg / d,10w） at the same time when models began to be made,the other treatment groups were dealed with just as the prevention groups 6 weeks later persisting for 4 weeks. Then rats were randomly taken for decollation in all six groups at the end of 10 th week. Colchicin group 5 × 10-5g / kg,CHSGS low-dose,mediate-dose and high-dose group（ 3. 15,6. 3,12. 6 g / kg）. The content of liver tissue interleukin-1（ IL-1） and tumor necrosis factor-alpha（ TNF-α） were tested by RIA,In situ hybridization assay and immunohistochemical S-P method were used to detect the expression of mRNA of TGF-β1 andα-SMA and there protein in hepatic fibrosis tissues. Result： Compared CHSGS mediate-dose group with model group,the content of HYP,IL-1,TNF-αin liver tissue were depressed significantly,the expressions of TGF-β1 andα-SMA genes were significantly lower in CHSGS 6. 3 g / kg group. Conclusion： Chaihushugansan have a positive action of treatment to hepatic fibrosis model rats,The mechanism of its effect is related with its inhibition the expression of TNF-α,IL-1,TGF-β1 and α-SMA in rats liver.
出处
《中药药理与临床》
CAS
CSCD
北大核心
2014年第5期8-11,共4页
Pharmacology and Clinics of Chinese Materia Medica
基金
河南省教育厅科学技术研究重点资助项目(12B360010)
关键词
柴胡疏肝散
肝纤维化
转化生长因子-Β1
Α-平滑肌肌动蛋白
羟脯氨酸
Chaihushugansan（柴胡疏肝散）； liver fibrosis； transforming growth factor-β1（TGF-β1）； a-smooth muscle actin（a-SMA）； hydroxyproline（HYP）
